|
MedImmune to present Phase IIb asthma data on benralizumab and …
News-Medical.net In the Phase IIb data being presented, both benralizumab and tralokinumab show promising safety and efficacy outcomes, suggesting they may offer important new therapeutic options for patients with specific forms of severe, uncontrolled asthma. |
View full post on asthma – Google News